Triple-therapy for chronic Hepatitis C infection: the neutrophil is not amused
B Leber, A Horvath, S Lemesch, V Stadlbauer, W Spindelböck, P Stiegler, R Stauber · Zeitschrift für Gastroenterologie · 2014 · Heft 05
Bibliografische Angaben
Zusammenfassung
Background and aims: Evidence is accumulating that antiviral triple-therapy for chronic hepatitis C (HCV) infection which combines the protease-inhibitors Telaprevir (TPV) or Boceprevir (BOC) with Peginterferon (P)/Ribavirin (R), leads to increased rates of clinically relevant infections. As neutrophils are crucial in protection against infections, we hypothesize that neutrophil function is affected by these triple-therapies. Methods: Neutrophil function of 38 patients with chronic HCV infection undergoing antiviral therapy (TPV/P/R: n = 11; BOC/P/R: n = 13; P/R: n = 16) and 18 healthy controls was investigated.…
